546 related articles for article (PubMed ID: 18349026)
1. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
Thijs V; Lemmens R; Fieuws S
Eur Heart J; 2008 May; 29(9):1086-92. PubMed ID: 18349026
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
Hankey GJ
Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
[TBL] [Abstract][Full Text] [Related]
3. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
4. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet therapy in the prevention of ischaemic stroke.
Verry M; Panak E; Cazenave JP
Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242
[TBL] [Abstract][Full Text] [Related]
6. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Diener HC
Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
[TBL] [Abstract][Full Text] [Related]
7. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Gebel JM
J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet agents and randomized trials.
Diener HC
Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
[TBL] [Abstract][Full Text] [Related]
10. Clinical inquiries. What is the best management for patients who have a TIA while on aspirin therapy?
Ahmed N; Coffey JB; Oh R
J Fam Pract; 2006 Jul; 55(7):627-8. PubMed ID: 16822451
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Biller J
J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
[TBL] [Abstract][Full Text] [Related]
12. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
Hankey GJ; Eikelboom JW
Neurology; 2005 Apr; 64(7):1117-21. PubMed ID: 15824331
[TBL] [Abstract][Full Text] [Related]
13. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Guthrie R
Adv Ther; 2011 Jun; 28(6):473-82. PubMed ID: 21547541
[TBL] [Abstract][Full Text] [Related]
14. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.
Li X; Zhou G; Zhou X; Zhou S
J Neurol Sci; 2013 Sep; 332(1-2):92-6. PubMed ID: 23871093
[TBL] [Abstract][Full Text] [Related]
16. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Forbes CD
Int J Clin Pract; 1997 Jun; 51(4):205-8. PubMed ID: 9287258
[TBL] [Abstract][Full Text] [Related]
17. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P; Sechenova O; Hennekens CH
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
[TBL] [Abstract][Full Text] [Related]
18. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
19. MATCH results: implications for the internist.
Lutsep HL
Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
[TBL] [Abstract][Full Text] [Related]
20. [Large trials in the secondary prevention of stroke].
Gensini GF; Simone I; Pantoni L; Inzitari D
Ann Ital Med Int; 1996 Oct; 11 Suppl 2():102S-109S. PubMed ID: 9004808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]